

Mexico City, December 2, 2015

GENOMMA LAB INTERNACIONAL ANNOUNCES ORGANIZATIONAL CHANGES

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”), one of the leading Companies in the Pharmaceutical and Personal & Beauty Care industries in Latin America, has announced the departure of Mr. Oscar Villalobos Torres who held the position of Executive Vice President, Chief Financial Officer, to focus on future projects not related to Genomma Lab nor its subsidiaries, effective December 15th, 2015. Genomma Lab thanks Mr. Villalobos for his many contributions to the Company over the years, and wishes him the very best in his next endeavor.

The Company is pleased to announce that Mr. Antonio Zamora Galland will be appointed as the new Executive Vice President and Chief Financial Officer of the Company, and will now assume responsibility for worldwide Finance operations, Information Technology and Investor Relations.

Mr. Zamora Galland joins Genomma Lab after serving as Chief Corporate Officer at Cydsa, a major chemical corporation. His professional career encompasses 25 years of experience in Consumer Packaged Goods, Management Consulting, Financial Services and Capital Markets. Before joining Cydsa, Mr. Zamora Galland served for 5 years as CFO of Grupo Lala, where he coordinated its IPO. Previously, he held the position of Financial and Strategic Planning Director at PepsiCo (Mexico and Central America) for 5 years. He also brings extensive experience from Management Consulting at McKinsey & Co. and EuroPraxis, as well as Corporate & Investment Banking at Bancomer and Banamex, respectively. Mr. Zamora Galland holds a Bachelor degree in Industrial Engineering from Universidad Panamericana and a MBA from Stanford University.

"We are very pleased to announce the arrival of Antonio as our new CFO. Antonio has a proven track record in publicly traded and private companies in Mexico, Europe and Latin America. His broad and proven leadership experience in Business Process Transformation will continue to support our fast-moving, high growth strategy in a challenging market environment", said Mr. Maximo Juda, Chief Executive Officer.

"I'm very pleased to join as a member of the Genomma Lab team. I am thrilled by the Company's vision and potential, and look forward in helping the Company to create significant value to Genomma Lab's shareholders", said Mr. Zamora Galland.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) is one of the leading Companies in the Pharmaceutical and Personal & Beauty Care industries in Latin America, with an increasing international presence. The Company sells and markets a broad range of premium branded products in these markets. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model that operates under the highest quality standards. Many of Genomma Lab's brands have reached leadership positions in terms of sales and market shares in the categories in which they compete.

Genomma Lab trades on the Mexican Stock Exchange under the ticker symbol "LABB".

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.